Traditionally, the development of novel therapeutics for metabolic diseases has relied mainly on high-throughput screening using biochemical or cell-based assays. While this approach represents a driving force in drug discovery, there is also a need to perform large-scale screens without disrupting inter-organ communication and tissue architecture, essential components for understanding the complexity of metabolic regulation and the identification of small molecules with appropriate biological activities in vivo. Hence, the zebrafish Danio rerio is gaining popularity in metabolic research and drug discovery, as this animal model allows screening of small molecules in the context of the whole-organism. Moreover, the zebrafish exhibits conserved function of the pancreas, liver and adipose tissue, which can be leveraged to identify novel targets in metabolic regulation, as well as to study the role of conserved genes associated with the risk of metabolic diseases in humans. Here we highlight recent advances in the identification of targets in metabolic regulation using the zebrafish as a model. 
Introduction
The zebrafish has been a prominent genetic model since the early 1990s [1] when its translucent embryos and genetic amenability allowed the first genetic screens for mutations that affect organ development in a vertebrate to be performed. Indeed, forward-genetic screens in zebrafish have identified mutations that disrupt orthologues of human genes with roles in diseases affecting the liver, pancreas and the intestine [2,3,4 ,5,6] . In addition, chemical-genetic screens in zebrafish have already rendered the first 'zebrafish' drug (ProHema), which is currently being explored in phase II clinical trials for improving hematopoietic stem cell engraftment and expansion [7, 8] . In regards to modelling metabolic diseases, however, the zebrafish as a model is still being validated. Thus, our aim in this brief review is to discuss both the strengths and weakness of the model for studying metabolic diseases. We first describe the development and the ontology of the main metabolic organs including the liver, pancreas and adipose tissue. In addition, we give striking examples from the recent literature showing conservation between zebrafish and mammals, including functional understanding of genes uncovered in zebrafish but identified by human genome wide association of metabolic traits, as well as the identification of small molecules which improve organ regeneration and glucose homeostasis.
Metabolic regulation in zebrafish
Typically, breeding a pair of zebrafish can deliver hundreds of fertilized eggs, which develop rapidly into larvae that have functional metabolic organs including the pancreas and liver ( Figure 1a ). Due to their small size (Figure 1b) , several embryos or larvae can fit and develop in a well of a 96-well plate, allowing their use in drug screening based on phenotypic examination of developmental features or by visualizing transgenic reporters with cell type-specific expression [9] (Figure 1 and Table 1 ). For example, the liver and pancreas can be observed directly using fluorescent reporters under a wide-field microscope after anesthetizing the larvae (Figure 1c ).
The functional role of the liver and the pancreas in regulating metabolism in zebrafish larvae is supported by several pieces of experimental evidence. For example, destruction of pancreatic beta-cells, using a genetic system, leads to a rapid hyperglycemia that returns to basal only after a sufficient number of beta-cells have regenerated [10, 11 ]. In addition, the larvae and adults show conserved responses to glucose-lowering agents such as insulin, extendin-4, or the antidiabetic drugs pioglitazone, glyburide, and metformin [12 ,13] .
An interesting metabolic feature of the early larvae is that their systemic glucose levels demonstrate changes even in the absence of external nutrition, which is reflective of alterations in hepatic glucose production. In particular, 
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An overview of the zebrafish model: (a) Breading a single pair of adult zebrafish can give rise to large clutches of fertilized eggs that develop externally into larvae with functional organs, including liver and pancreas. (b) The top panel shows Tg(fabp10:dsRed); Tg(ptf1a:GFP) larvae [79] , which mark the hepatocytes (red) and the exocrine pancreas (green), respectively. The bottom panel shows Tg(ins:Kaede) larvae [11 ] , which mark the pancreatic beta-cells (green, arrow). The larvae were imaged at 4 days post-fertilization (dpf) using a fluorescent wide-field microscope. 1phenyl 2-thiourea (PTU) was applied to the fish water in order to prevent pigmentation. The bright-field images were overlaid on the fluorescence images. (c) Due to their small size, several larvae can fit into a single well of a 96-well plate allowing for different screening applications. (i) High-content screening is made possible using cell type specific reporters such as the fluorescence ubiquitination cell cycle indicator (FUCCI), expressed under the insulin promoter. In this example, beta-cells that proliferate express a green fluorescent protein, whereas non-proliferating beta-cells exhibit red fluorescence [30] . (ii) Liver regeneration can be studied using transgenic lines in which the bacterial nitroreducatase (NTR) enzyme is placed under control of the hepatocyte-specific fabp10a promoter [17 ,18 ,19 ]. NTR converts the nontoxic prodrug metronidazole (Mtz) into a cytotoxic drug, thereby ablating specifically the NTR-expressing cells, in this case the hepatocytes (blue). Hepatocyte regeneration is mediated via trans differentiation of biliary epithelial cells (red). (iii) Fluorescent reporters of beta-cells (red) allow to screen for compounds that increase the beta-cell mass via proliferation or de-novo beta-cell formation. (iv) The zebrafish larvae exhibit dynamic changes in glucose levels based on their nutritional status and gluconeogenesis, enabling screens for small molecules that control glucose metabolism [12 ,15 ]. (v) Genetic manipulations are feasible in zebrafish using mutagenesis, genome editing or generation of transgenic lines that express candidate genes in specific cells or organs. around 5 days post fertilization (dpf), zebrafish larvae exhaust the maternally derived stores of nutrients in their yolk cell, in which lipids are processed prior to mobilization to the embryonic body [14] . During this period of yolk exhaustion, the liver exhibits a mammalian-like response to fasting, and upregulates gluconeogenesis to compensate for the decline in energy stores, leading to increased glucose concentrations [15 ,16 ] . This response is implemented by an increase in the expression of the fasting response gene cytosolic phosphoenolpyruvate carboxykinase ( pck1) in hepatocytes [15 ,16 ] . Notably, several genetic and environmental perturbations in zebrafish can model liver diseases such as fibrosis and steatosis ( Table 2 ). In addition, it is important to mention the striking regenerative capacity of the zebrafish liver, even after near-complete hepatocyte ablation. This paradigm has allowed the identification of novel pro-regenerative signals and small molecules that control this process [17 ,18 ,19 ,20] . These aspects have been reviewed in detail elsewhere [21, 22] and are summarized in Table 2 .
The zebrafish larvae begin independent feeding at around 6 dpf, and grow rapidly as they develop into juveniles (at around 30 dpf) and subsequently into sexually mature adults at around 90 dpf. With the onset of feeding, blood glucose concentrations become nutrient dependent and follow a meal-based pattern. Glucose can be measured in adults using a standard glucometer after collecting a few micro-litres of blood [13] , as well as in larvae after performing a fluorimetric glucose assay [16 ] . In addition, with the start of independent feeding white adipocytes begin to accumulate in both subcutaneous and intra-abdominal positions, the latter resembling the visceral adipose tissue (VAT) found in humans [23, 24 ] . Notably, the adipocytes can be visualized non-ivasively using lipophilic fluorescent dyes, as their mass shrinks or expands in response to prolonged fasting or overfeeding, respectively [24 ] . Several genetic models of increased adiposity have been established in zebrafish (Table 2) . Of note, zebrafish are poikilothermic and do not possess the thermogenic brown adipocytes present in mammals [23] .
Target identification in glucose homeostasis
As mentioned above, the early larvae exhibit natural increases in glucose levels, which have provided a simple in vivo setting to search for glucose-lowering agents [16 ] . Recently, Nath et al. applied a fluorimetric glucose detection-assay in order to screen >7000 compounds for novel glucose-lowering agents. This screen identified alexidine, which inhibits the PTEN-like mitochondrial phosphatase PTPMT1 and leads to a decrease in glucose concentrations by activating succinate dehydrogenase and increasing energy expenditure [12 ] . A different screen utilized the expression of firefly-luciferase placed under the control of the fasting response gene promoter pck1, generating a robust transgenic reporter of hepatic gluconeogenesis. By screening thousands of FDA-approved drugs using a bioluminescence plate-reader, Gut et al. identified selective and high-affinity ligands (PK 11195 and Ro5-4864) for the Translocator Protein (TSPO), which promoted a fasting-like energy state in the zebrafish larvae [15 ] . TSPO, an outer mitochondrial membrane protein, controls the import of cholesterol and the subsequent production of steroids and neurosteroids [25] . Importantly, the TSPO ligands identified in zebrafish protected high-fat diet-induced obese mice from hepatosteatosis and glucose intolerance, demonstrating that small molecules identified using zebrafish can exhibit conserved roles in mammalian metabolic regulation [15 ] . In addition to the assays mentioned above, fluorescein-tagged glucose bioprobes such as 2-NBDG can be applied to screen for small molecules that improve glucose uptake in peripheral tissues [26 ] , which has identified novel insulin mimetics (Table 1) .
Identification of targets in pancreatic beta-cell plasticity
The zebrafish provides unique advantages for studying beta-cell development and regeneration, since their betacells can be visualized using fluorescent proteins expressed under the zebrafish insulin promoter (Figure 1b) [27] . Zebrafish beta-cells originate from dorsal and ventral pancreatic buds that coalesce to form the embryonic islet. Similar to mouse islets, the beta-cells are located in the islet core, whereas alpha-cells occupy the periphery. The zebrafish islet is also densely vascularized and innervated [27, 28] . During postembryonic development, the pancreas forms numerous additional secondary islets embedded in the acinar cells, which differentiate from Sox9b-postive progenitors [27] . This differentiation resembles the secondary transition seen in the mouse pancreas [29] . Notably, the zebrafish beta-cells respond to over-nutrition by increasing their mass through proliferation and differentiation [30,31 ,32] but also fail, like their mammalian counterparts, during conditions of insulin resistance. This was recently shown using a zebrafish transgenic model of skeletal-muscle insulin resistance [33 ] . In addition, work from our group recently characterized the development of beta-cell functionality using the genetically encoded calcium indicator GCaMP6s. We found that in early larvae (4 dpf), a majority of the beta-cells exhibit calcium influx upon stimulation with glucose in the physiological range [34 ] . Moreover, we showed that the larval beta-cells turn on the expression of the zebrafish ortholog of the mammalian marker of beta-cell maturity, Urocortin 3 (Ucn3) [35] . Thus, our findings open the doors to use the translucent zebrafish larvae in order to identify signalling pathways that control beta-cell functional maturation [36] , an important step for the differentiation of functional human beta-cells from stem cells [37] .
Remarkably, beta-cells in zebrafish appear to be more regenerative than mammalian beta-cells. Even in adults, Beta-cell ablation in adults and lineage tracing of centro-acinar cells Beta-cells regenerate via differentiation from centro-acinar cells [30] Constitutive beta-cells ablation using the diphtheria toxin a (DTA) during development Beta-cell ablation triggers a regenerative response in the pancreatic duct, which is dependent on nutrient intake and mTOR signalling [39] Beta-cell ablation in larvae Beta-cell regeneration via alpha to beta-cell trans-differentiation. A role for glucagon in promoting trans-differentiation. [40] Beta-cell ablation in larvae A role for IGFBP1 in beta-cell regeneration by promoting alpha-to beta-cell transdifferentiation.
Zebrafish mutants affecting liver and pancreas function
[17
] Near-complete ablation of hepatocytes in larvae
Regeneration of hepatocytes from biliary epithelial cells [58 ] Leptin receptor (lepr) mutants lepr deficient zebrafish show alterations in beta-cell mass and glucose homeostasis but do not exhibit hyperphagia or increased adiposity [63 ] pdx1 mutants pdx1 deficient zebrafish show reduced beta-cell mass, impaired proliferation, decreased insulin production, and elevated glucose [64] gcgra and gcgrb mutants Glucagon receptor mutants show alpha cell hyperplasia Model to screen for chemical and genetic suppressors of glucagon signalling [65 ] harvest moon mutants Glutamine-fructose-6-phosphate transamidase (Gfpt1) mutants exhibiting hepatic steatosis and increased TAGs. [66] Lxra (nr1h3) mutants nr1h3 mutants are sensitive to the effects of high-cholesterol challenge, leading to hepatic steatosis [67 ] trappc11 mutants Trappc11 is required for proper protein folding. A model of ER stress and hepatic steatosis [68 ] slc16a6a mutants Slc16a6a is a hepatic ketone body transporter required during fasting. A model of hepatic steatosis Zebrafish mutants affecting the adipose tissue [56 ] plxnd1 mutants plxnd1 is implicated in body fat distribution and type 2 diabetes. The zebrafish mutants exhibit reduced lipid deposition in VAT and protection from high-fat diet [69 ] sox6 mutants Reduced lipid droplets in number and size [57 ] cyp2r1 mutants A model of vitamin D3 deficiency. The mutants exhibit growth-retardation and obesity [70 ] gh1 mutants Growth hormone deficient zebrafish show dwarfism and increased adiposity
Genetic and environmental models of diabetes, obesity and hepatic dysfunction [71] Overexpression of the melanocortin antagonist agouti-related protein (AgRP)
Increased adiposity and linear growth [72] Transgenic overexpression of exogenous human Akt1
Increased fat deposition, hyperplastic adipocytes, glucose intolerance and inflammation [33 ] Dominant-negative IGF-IR expression in skeletal muscle
Reduced beta-cell mass in adults and impaired glucose clearance. [73] Overfeeding with brine shrimp (artemia) Increased BMI, hypertriglyceridemia and hepatic steatosis fasting glucose levels normalize within two weeks of nearcomplete beta-cell ablation, without the need for insulin administration to sustain survival [10] . This striking regenerative capacity relies on de-novo beta-cell formation through differentiation from centro-acinar cells [38 ] or from the conversion of alpha cells into beta-cells [39], followed by proliferation of the newly formed beta-cells. The distinction in regenerative potential between zebrafish and mammals provides an intriguing model to search for novel pro-regenerative signals (Table 2) . For example, a genetic screen recently found that the insulin like growth factor binding protein 1 (IGFBP1) is upregulated in the liver in response to beta-cell ablation. In turn, IGFBP1 potentiates beta cell regeneration by promoting alpha-to beta-cell trans-differentiation [40] . Another recent study also identified a role for a conserved bacterial protein (beta-cell expansion factor A), which is secreted from the intestinal microbiota and appears to influence beta-cell mass plasticity during development [41 ] . It remains to be seen if these signals can be applied to boost mammalian beta-cell regeneration.
Whole-organism screens from small molecules that increase beta-cell numbers
The search for novel beta-cell trophic factors is under intense investigation using mammalian cell based approaches, with the hope of identifying new therapies for beta-cell mass replenishment in diabetes [42] . In contrast to the cell-based approaches, the zebrafish allows the identification of molecules which may stimulate betacell mass expansion indirectly, for example through interorgan communication. Several chemical screens have been performed, aimed at identifying compounds that enhance beta-cell regeneration or promote beta-cell proliferation and differentiation [11 ,43 ,44 ,45 ]. These screens have identified both novel and conserved players in beta-cell mass expansion (Table 1) . For example, the development of a system for selective beta-cell-ablation allowed $7000 small molecules to be screened for enhancers of beta-cell regeneration. This screen identified the adenosine agonist 5 0 -N-ethylcarboxamidoadenosine (NECA) as a potent inducer of regeneration. NECA also enhanced beta-cell regeneration in a mouse model of diabetes by promoting beta-cell proliferation [11 ] . Moreover, deletion of the adenosine receptor A2 in mouse beta-cells impaired compensatory beta-cell proliferation during pregnancy [46] . A second screen used an innovative technology based on the fluorescence ubiquitination cell cycle indicator (FUCCI) [47] that allows the direct quantification of beta-cell proliferation based on the expression of GFP specifically in proliferating cells [30] (Figure 1c) . Screening 900 small molecules using the FUCCI reporter system identified clinically-approved drugs that modulate three signalling pathways: serotonin, retinoic acid and glucocorticoids [45 ] . Given the conserved role of serotonin signalling [48] and glucocorticoids [49] in mammalian beta-cell proliferation, these results highlight the great potential for screening in zebrafish.
Finally, a more recent approach employed robotics to mechanise parts of the protocol, including embryo and drug dispensing, whilst also using automatic detection and quantification of GFP-positive beta-cells, as a proxy for beta-cell mass. This streamlined highthroughput screening (HTS) approach enabled to screen FDA-approved at several different concentrations in >500 000 transgenic zebrafish larvae [39] . As with the FUCCI screen, this approach also identified serotoninenhancing compounds and glucocorticoids to activate beta-cell proliferation. In addition, it identified a novel role for NF-kB-signalling inhibition in promoting de-novo beta-cell formation [44 ] . In conclusion, the zebrafish is a Overfeeding with brine shrimp (artemia) High fasting blood glucose, glucose intolerance and insulin resistance [75] Induction of hyperglycaemia through immersion in high glucose solution Diabetic retinopathy [76 ] Immersion of larvae in fructose solution Hepatic steatosis, mitochondrial and ER defects as well as activation of inflammatory and lipogenic genes. [77] Immersion of larvae in ethanol Hepatic steatosis associated with oxidative stress and activation of the unfolded protein response [41 ] Gnotobiotic model in embryos and larvae Exhibit reduced beta-cell number during development [14] Lipid profiling of the yolk cell and pharmacological inhibition of PPARg Identification of the yolk as a site of active lipid metabolism Pharmacological inhibition of PPARg changes the lipid profile of embryos [78] Streptozotocin induced beta-cell death followed by recovery Hyperglycaemia-induced DNA methylation as a potential contributor to the metabolic memory phenomenon and epigenetic alterations in diabetes.
powerful model for screening compounds for beta-cell expansion and regeneration. However, all compounds identified to date are yet to be validated using primary human islets and tissues, which is a critical preclinical step. In addition, novel screens targeting beta-cell function and protection await to be developed in the zebrafish.
Zebrafish genetics in target identification
One key remaining question is whether zebrafish metabolism and gene function are conserved enough to accurately model human diseases. Certainly, the zebrafish is a powerful genetic model, as it allows the generation of lines with tissue-specific over-expression of candidate genes with ease [50] . Moreover, CRISPR (clustered regularly interspaced short palindromic repeats) and TALENs (transcription activator-like effector nucleases) can be used for targeted gene-disruption [51] . In addition, novel optogenetic methods for controlling gene function have been developed [52] , as they are ideally suited to the translucent zebrafish embryos and larvae. Thus, the zebrafish holds the promise to enhance our ability to study candidate genes with relevance to human metabolic dysfunction, provided they exhibit sufficient conservation.
In the future more information regarding the metabolic conservation between mammals and zebrafish will become available. However, many studies have already modelled genetic and environmental factors which impact on metabolic diseases using zebrafish (Table 2) . Remarkably, three recent papers depict striking conservation between zebrafish and human gene function in metabolic processes. For example, a SNP (rs8004664) in the first intron of the FOXN3 gene associates with human fasting blood glucose [53] . Karanth et al. found that hepatocytes from donors carrying rs8004664 exhibit increased expression of a dominant FOXN3 transcript [54 ] . Transgenic over-expression of either zebrafish or human FOXN3 in zebrafish hepatocytes led to hyperglycemia, and enabled a mechanistic analysis of FOXN3 in hepatic gluconeogenesis, along with the identification of MYC as a conserved downstream target [54 ] . A second example relates to plexind1 ( plxnd1), a candidate gene in body fat distribution and type 2 diabetes identified by GWAS [55] . Interestingly, zebrafish plxnd1 mutants exhibited reduced lipid deposition in WAT and were protected from insulin resistance induced by a high-fat diet. In agreement with this correlation, higher human plxnd1 mRNA-expression was positively associated with type 2 diabetes, suggesting that lower expression of plxnd1 might provide protection from metabolic dysfunction [56 ] . Finally, a recent study used the powerful genetics of zebrafish to help clarify the role of vitamin D3 in adipose biology. To probe for a role of vitamin D3 in metabolic regulation, Peng et al. generated two new independent cyp2r1-deficient zebrafish lines using targeted gene-disruption. These mutants exhibited growth retardation and obesity with increased adiposity, consistent with the proposed role for vitamin D-deficiency in increasing the risk of metabolic disease. Importantly, the obesity and growth-retardation phenotypes were rescued with 25(OH)D3-supplementation, which is the active hormonal metabolite of vitamin D3. Molecular analysis further demonstrated that the vitamin D receptor can activate the expression of pgc1a, a master regulator of mitochondrial biogenesis, a process critical for fatty-acid oxidation [57 ] . Altogether, these studies provide examples of evolutionary conserved players in metabolic regulation, which have greatly increased the interest in using zebrafish to model human disease. However, as more studies are published, intriguing exceptions to this conservation maybe uncovered. For instance, leptin receptor-deficient zebrafish show disrupted glucose homeostasis without the appearance of the hyperphagia or obesity described in the mouse model [58 ] .
Conclusion
The key examples we highlighted demonstrate the versatility of the zebrafish as a model to search for targets of metabolic regulation. In the future, the zebrafish field may tackle additional milestones, such as using the model to identify small molecules and genetic networks that regulate the control of appetite [58 ] , the central regulation of glucose homeostasis, the role of inflammation in metabolic dysfunction [59 ,60] , and the interplay between the microbiota and metabolism [41 ] . Furthermore, the high regenerative capacity of the zebrafish could be explored to unlock novel signals that boost regeneration of other metabolic organs, not just beta-cells. However, many challenges remain, for example, it will be necessary to develop reliable methods for the generation of tissue-and cell-specific gene knockouts. In addition, physiological models of immune-mediated beta-cell destruction and age-related complications of metabolic disease need to be developed in order for zebrafish to reach their full potential as a powerful pre-clinical model.
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